-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Synovial Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Synovial Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Synovial Sarcoma Drug Details: LB-100 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-2102 in Neuroendocrine Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-2102 in Neuroendocrine Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-2102 in Neuroendocrine Carcinoma Drug Details: LB-2102 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-1908 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-1908 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-1908 in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Fallopian Tube Cancer Drug Details: LB-100 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Soft Tissue Sarcoma Drug Details: LB-100 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Nerve Sheath Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Nerve Sheath Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Nerve Sheath Tumor Drug Details: LB-100 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: LB-100...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Small-Cell Lung Cancer Drug Details: LB-100 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-2102 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-2102 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-2102 in Small-Cell Lung Cancer Drug Details: LB-2102 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-101 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-101 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-101 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...